ONCAlert | Upfront Therapy for mRCC

EGFR+ Lung Cancer 1 MORE >>

Osimertinib has demonstrated a statistically significant and clinically meaningful improvement in overall survival compared with standard first-generation EGFR tyrosine kinase inhibitors in patients with newly diagnosed EGFR-mutated non–small cell lung cancer, according to updated findings from the phase III FLAURA trial.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.